

**Supplementary Table 6: Primers for qPCR**

<b>Gene</b>	<b>Forward</b>	<b>Reverse</b>
<i>ActinB</i>	AAGGCCAACCGTGAAAAGAT	GTGGTACGACCAGAGGCATAC
<i>Bdnf</i>	GATGCCGCAAACATGTCTATGA	TAATACTGTCCACACACGCTCAGCTC
<i>c-Fos</i>	GGGAGGACCTTACCTGTTCG	AGGCCAGATGTGGATGCTT
<i>Egr1</i>	CCTATGAGCACCTGACCACA	TCGTTTGGCTGGGATAACTC
<i>FosB</i>	CGAGAAGAGACACTTACCCCA	GTTTCCGCCTGAAGTCGATCT
<i>Gad67</i>	GCTTGTGCCCTCTGGTA	AGATGGCCTAGATGTGTCAGC
<i>Igf1</i>	TGGATGCTCTTCAGTTCGTG	GCAACACTCATCCACAATGC
<i>Nptx2</i>	AGAGGGTGACTGAGCTGGAG	CTTCTTGATCTTGCCATACAGGT
<i>Nrn1</i>	GTTTTGATCATTCCACTGCAC	CCCACACTCTTGTTGTTTTCG
<i>Npas4</i>	AGGGTTTGCTGATGAGTTGC	CCCCTCCACTTCCATCTTC
<i>Pvalb</i>	GGCAAGATTGGGGTTGAAG	AGCAGTCAGCGCCACTTAG
<i>Sst</i>	CAGCTGAGCAGGACGAGAT	TTGCTGGGTTCGAGTTGG
<i>Tubb3</i>	CGACAATGAAGCCCTCTACGAC	ATGGTGGCAGACACAAGGTGGTTG
<i>VGlut1</i>	CCCCCAAATCCTTGCACT	CAAATGGCCACTGAGAAACC
<i>Vip</i>	AACTACACCCGCCTCAGAAA	AAAGTCTGCAGAATCTCCCTCA

### Supplementary Table 7: Primers used for cloning of riboprobes

Restriction sites used for cloning are underlined

<b>Gene</b>	<b>Forward</b>	<b>Reverse</b>
<i>Igfl</i>	ACTTCTCGAGGATAAAGATACACATC ATGTCGTC	AGAGGCGGCCGCCTATACTTAGGTTA CATACTAAC
<i>Gad67</i> ( <i>Gad1</i> )	AGCACTCGAGCTGCTCGTTACAAGTA CTTCC	AAGCGCGGCCGCCTCTGACATACAG CCTGAG
<i>Pvalb</i>	CCAACTCGAGGGATGTCGATGACAGA CGTG	TCAGGCGGCCGCTCACAGCAAAGTCA AAAGCAA
<i>Sst</i>	GTCGCTCGAGCCTGAGGACCTGCGAC TAGA	AATTGCGGCCGCAGGGTCAAGTTGAG CATCG
<i>Vip</i>	ATAACTCGAGACATCAATTTTCCTCGA TTGC	AGACGCGGCCGCCCTTCCTAGAGCA GAACTTC

**Supplementary Table 8: AAV stocks and uses**

<b>Construct</b>	<b>Packaging</b>	<b>Titer</b>	<b>Produced by</b>	<b>Experiments</b>
pAAV-shLuc-hUbc-Flex-EGFP	AAV 2/1	$1.2 \times 10^{12}$ /ml	UNC Viral Core	Sparse infection upon P14/15 injection into visual Ctx
pAAV-shIgf1-1-hUbc-Flex-EGFP	AAV 2/1	$7.3 \times 10^{11}$ /ml	UNC Viral Core	Sparse infection upon P14/15 injection into visual Ctx
pAAV-shIgf1-1-hUbc-Flex-EGFP	AAV 2/1	$1.4 \times 10^{12}$ /ml	UNC Viral Core	Sparse infection upon P14/15 injection into visual Ctx
pAAV-shLuc-hUbc-Flex-EGFP	AAV 2/9	$1.8 \times 10^{12}$ /ml	UNC Viral Core	P3 intracortical injection P18-20 bilateral injections into visual Ctx for MD experiments
pAAV-shIgf1-1-hUbc-Flex-EGFP	AAV 2/9	$1.4 \times 10^{12}$ /ml	UNC Viral Core	P3 intracortical injection P18-20 bilateral injections into visual Ctx for MD experiments
pAAV-shIgf1-1-hUbc-Flex-EGFP	AAV 2/9	$2.4 \times 10^{12}$ /ml	UNC Viral Core	P3 intracortical injection
pAAV-hUbc-Flex-SSHA Igf1.4Myc-F2A-EGFP	AAV 2/9	$2.2 \times 10^{15}$ gc/ml	CHB Viral Core	P3 intracortical injection
pAAV-hUbc-Flex-F2A-EGFP	AAV 2/9	$7.8 \times 10^{14}$ gc/ml	CHB Viral Core	P3 intracortical injection